about
FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cellsLong-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods.Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression.Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane.New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin.Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity.A proteomic approach to identify endosomal cargoes controlling cancer invasiveness.CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer.p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism.A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma.Practicalities of using an adaptive design for decision making within the optima trial: optimal personalized treatment of early breast cancer using multi-parameter tests.A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours.Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells.A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer.Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice.Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial.Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.Stochastic Pharmacokinetic-Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA).The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective reviewResponse to: ‘Letter to the editor, European Journal of Cancer’, commenting on ‘Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma’Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levelsAuto-immune neutropenia occurring in association with malignant melanomaLoading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer
P50
Q27316587-245C382A-74E2-4723-9A3B-8E55FDB4D380Q30371966-0D00F90F-E391-4AFE-BA3A-813BEEEC5619Q30527787-090DFDF8-A4AE-45EE-B318-5E52E3AF47B5Q36426956-458DA4AD-D907-46DA-AC12-9EE663049FFBQ37022428-0F73CE9B-1D3F-4C30-9108-8A5EE7D96614Q37355561-30955A39-3A15-4DD2-9E9D-64A667ED6507Q37355919-C36BE735-8C40-4699-A318-ED2B061B18AEQ37486753-AD99E810-B9A7-4AEA-83A8-41359AE8C7FAQ37651981-7D3A4CF2-F054-4168-BF2D-BA61FD0D6F8EQ38722550-3A33A2D9-B3AA-444C-B670-BD5BB7CA3834Q38976198-3ADEE200-DCA3-46A9-9589-A7D6194E289EQ40164009-513D76E5-5780-49B8-985F-138C30E20F18Q42695640-0E2896BD-8B24-4FCF-933E-F2E642BC4E63Q43461446-A85A9B8F-DF09-4385-9D35-257E717C707FQ45991697-6C7B6987-DDEB-477E-ABCF-F556DA2900D7Q46132954-B20CD4B8-155E-4E4F-80F1-6995BC68C543Q47169465-7E4F5F4B-880A-47E6-8E63-E45E4581529AQ47634886-DF32CF74-5FDE-43A7-AB53-33C54A35C66DQ51835224-188011C2-4F6C-45CD-B21E-147DDD9FF70DQ52804928-CCC99B33-E5E9-42CB-AFB2-9CB0CFF41D34Q52868338-A6BA2D9A-B4C5-4294-AEE1-A9B40EEA1602Q53111208-7C20A459-F7BE-412D-A5FD-C9DF3442D27AQ54993802-CD1B1CB7-61D1-4AC6-AA3C-188AC58D7666Q57074665-1B28D9A4-CDB7-4F7A-BF0A-29191066551FQ57750216-52D00DBF-B1FE-4360-BEB0-0538612ED90AQ59801568-D841D661-0C63-4CAD-BAD7-CBFD8B63CD7DQ78620502-049AEBEA-213E-4441-AD50-E41209A33268Q86124094-88207B7E-0A24-4A74-B929-3D985FFF76EE
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Iain R Macpherson
@ast
Iain R Macpherson
@en
Iain R Macpherson
@es
Iain R Macpherson
@nl
type
label
Iain R Macpherson
@ast
Iain R Macpherson
@en
Iain R Macpherson
@es
Iain R Macpherson
@nl
prefLabel
Iain R Macpherson
@ast
Iain R Macpherson
@en
Iain R Macpherson
@es
Iain R Macpherson
@nl
P106
P21
P31
P496
0000-0003-4295-8885